| Bioactivity | NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod (HY-B0180)-induced psoriasis in mice[1]. |
| Invitro | NJK14047 (3-10 μM) 抑制 Lipopolysaccharid (HY-D1056) 刺激的人 SW982 滑膜细胞中炎症细胞因子 IL-1β，TNF-α，IL-6，IL-17A，RANKL 和 MMP-3 的表达[ 1]。NJK14047 (3-10 μM) 剂量依赖性地抑制初始 CD4+T 细胞向 Th1、Th2 和 Th17 细胞分化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> NJK14047 相关抗体: |
| In Vivo | NJK14047 (2.5 mg/kg，腹腔注射，7-21 天) 可改善 DBA-1J 小鼠模型中胶原诱导的类风湿性关节炎 (CIA) 和 BALB/c 小鼠模型中 Imiquimod (HY-B0180) 诱导的银屑病 (IIP)，抑制 Th1，Th2，Th17 和 Treg细胞因子表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1800576-41-3 |
| Formula | C27H27NO5 |
| Molar Mass | 445.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800. |